spacer
home > white papers > Pandemic respiratory vaccine clinical trials: a departure from business as usual - ICON plc
WHITE PAPERS
logo_ICON_plco.jpg

ICON plc

phone +353 1 291 2883
email info-clinical@iconplc.com
web http://www.iconplc.com
email ICON plc, Headquarters, South County Business Park, Leopardstown, Dublin 18, Ireland

Pandemic respiratory vaccine clinical trials: a departure from business as usual

Around the world, the “V” words are on everyone’s lips: Virus and Vaccines. In response to the urgent need for a vaccine for COVID-19, researchers are, at time of publication, running 500+ clinical trials (and counting) on a number of antivirals, antibodies and vaccines. Promising possibilities range from novel new drugs/vaccines, repurposing treatments currently indicated for HIV, Ebola and malaria, to monoclonal antibodies and immune serum.
Pandemic respiratory vaccine clinical trials: a departure from business as usual
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Global pharma industry gathers at CPhI Worldwide 2021 as surge in partnering expected in 2022

Over 25,000 online and 23,000 in person attendees at the world’s largest pharma trade exhibition. CPhI Worldwide (9-11 November, 2021), which held its first in-person event since 2019, hosted the global pharma community at the Fiera Milano, Milan, welcoming exhibitors and attendees from 146 countries.
More info >>


White Papers

Running Smarter Trials With Data-Driven Monitoring

PAREXEL

Clinical monitoring remains one of the most important and most costly activities in the clinical research paradigm.  Monitoring provides the operational transparency required by investigators, sponsors, and regulators to make informed decisions about site performance, patient safety, and overall study progress. Yet unlike many clinical trial activities, which have been steadily transformed by technology, the monitoring function itself has changed little.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement